Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

The number of patients at risk for fungal infections continues to increase because of
improved survival of medically and surgically complex patients, new indications for …

Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost.
In recent times, a rising incidence of fungal infection and antifungal resistance is occurring …

The field of invasive fungal disease (IFD) continues to evolve rapidly as new antifungals,
including those with novel mechanisms of action, are being developed or have recently …

Manogepix (APX001A) is the active moiety of the drug candidate fosmanogepix (APX001),
currently in clinical development for the treatment of invasive fungal infections. We …

Background Invasive aspergillosis is associated with significant morbidity and mortality in
patients with haematologic malignancies and haematopoietic cell transplant recipients. The …

Triazoles remain first-line agents for antifungal prophylaxis in high-risk haemato-oncology
patients, but their use is increasingly contraindicated due to drug–drug interactions and …

Potent fungicidal activity is one of the key factors of antifungals to overcome invasive
pulmonary aspergillosis (IPA). To date, quantification of Aspergillus DNA in the lungs and …

Las especies de los géneros Candida y Aspergillus son las causas más frecuentes de
micosis invasivas. Este tipo de infección afecta con mayor frecuencia a pacientes …

Aspergillus species are ubiquitous fungi found in the environment worldwide. The most
common Aspergillus species causing diseases in humans are A. fumigatus, A. flavus, A …